Analytical methods for nebivolol quantification in pharmaceutical formulations and biological matrices: a comprehensive review

Analytical methods for nebivolol quantification in pharmaceutical formulations and biological matrices: a comprehensive review

Abstract Nebivolol, a beta-blocker commonly prescribed for the treatment of hypertension and heart failure, functions by decelerating heart rate and promoting vasodilation, thereby enhancing blood flow and reducing blood pressure. Distinctively, nebivolol elevates nitric oxide levels, facilitating s...

Full description

Saved in:

Bibliographic Details
Main Authors:	Kurdo A. Abdullah, Aryan Fathulla Qader, Rebaz Anwar Omer, Rebaz Obaid Kareem, Musher Ismael Salih
Format:	Article
Language:	English
Published:	Springer 2025-06-01
Series:	Discover Chemistry
Subjects:	Nebivolol Pharmaceutical analysis Beta-blockers Pharmacology Hypertension
Online Access:	https://doi.org/10.1007/s44371-025-00213-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines
by: V. I. Makolkin
Published: (2010-12-01)

The role of nitric oxide in improving endothelial function andcardiovascular health: focus on nebivolol
by: G. L. Bakris, et al.
Published: (2011-04-01)

HIGH SELECTIVE LONG-ACTING Β1-BLOCKER WITH A VASODILATING EFFECT NEBIVOLOL IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE
by: V. P. Lupanov
Published: (2015-12-01)

EFFICACY OF NEBIVOLOL IN TREATMENT OF WOMEN WITH CORONARY HEART DISEASE
by: N. A. Koryagina, et al.
Published: (2014-12-01)

URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
by: M. P. Savenkov, et al.
Published: (2016-01-01)

The role of vasodilating β-blockers in controlling arterial hypertension as a means of reducing cardiovascular and stroke risk
by: Jan N. Basile
Published: (2011-06-01)

COMPARATIVE PHARMACOKINETICS AND EFFECT ON THE HEMODYNAMICS OF ORIGINAL AND GENERIC NEBIVOLOL IN HEALTHY VOLUNTEERS
by: E. I. Bambysheva, et al.
Published: (2016-05-01)

THE EFFECT OF NEBIVOLOL ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH MILD HYPERTENSION
by: I. L. Tepoyan, et al.
Published: (2015-09-01)

Levofloxacin Determination in Pharmaceutical Tablets by Sensitive Spectrofluorometric Method with L-Tryptophan as a Fluorescent Probe
by: Kurdo A. Abdullah, et al.
Published: (2025-06-01)

Nebivolol effect on oxidative biomarkers in Tamoxifen-Induced Hepatotoxicity in Female White Albino Rats: In Vivo Study
by: Noor Ahmed Hammadi, et al.
Published: (2025-05-01)

Nebivolol therapy and reduction of intravascular platelet activity in patients with atrial hypertension and metabolic syndrome
by: I. N. Medvedev
Published: (2006-06-01)

THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE
by: A. B. Khadzegova
Published: (2014-09-01)

THE ROLE OF VASODILATING BETA-BLOCKERS IN PATIENTS WITH HYPERTENSION AND THE CARDIOMETABOLIC SYNDROME
by: A. A. Taylor, et al.
Published: (2011-08-01)

EFFECTS OF NEBIVOLOL VS NADOLOL ON GLUCOSE AND LIPID METABOLISM IN OVERWEIGHT HYPERTENSIVE PATIENTS. A OPEN RANDOMIZED CONTROLLED STUDY
by: E. R. Berngardt, et al.
Published: (2003-06-01)

NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
by: R. L. Dzhanaeva, et al.
Published: (2012-02-01)

Pleiotropic activity of antihypertensives in atherothrombogenesis. Nebivolol: increasing possibilities and reducing restrictions
by: M. G. Bubnova
Published: (2008-12-01)

REGULATORY-ADAPTIVE STATE IN EVALUATION OF BISOPROLOL AND NEBIVOLOL THERAPY EFFECTIVENESS FOR VENTRICULAR ARRHYTHMIA
by: I. Z. Shubitidze, et al.
Published: (2016-12-01)

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
by: L. I. Olbinskaya, et al.
Published: (2007-02-01)

HEMODYNAMIC AND METABOLIC EFFECTS OF NEBIVOLOL IN LOCOMOTIVE CREW STAFF WITH NEWLY DIAGNOSED ARTERIAL HYPERTENSION
by: I. V. Osipova, et al.
Published: (2016-01-01)

Assessment of pleiotropic effects of nebivolol: influence on microcirculation parameters and bone tissue in postmenopausal women with mild arterial hypertension
by: I. L. Tepojan, et al.
Published: (2016-04-01)

MODERN POTENTIAL IN THE TREATMENT OF METABOLIC SYNDROME PATIENTS - FOCUS ON ENDOTHELIUM
by: V. B. Mychka, et al.
Published: (2014-03-01)

NEBIVOLOL IN TREATMENT OF STABLE EXERTIONAL ANGINA PECTORIS
by: Y. V. Gavrilov, et al.
Published: (2015-12-01)

Optimization and evaluation of nebivolol hydrochloride loaded transferosomes using Box-Behnken experimental design
by: P V Shelke, et al.
Published: (2024-08-01)

Nebivolol Mitigate the Hepatic Expression Level of Inducible and Endothelial Nitric Oxide Synthase in Tamoxifen-Induced Oxido-Inflammatory Changes in Female Rats
by: Noor Ahmed Hammadi, et al.
Published: (2025-06-01)

Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
by: V. I. Makolkin, et al.
Published: (1970-01-01)

Development and validation of stability indicating RP-HPLC method for nebivolol by using the DOE approach
by: Anant Ghongade, et al.
Published: (2025-06-01)

A Comprehensive Study of Pharmacologic Complexity: Study of Interactions and Properties of Paracetamol, Aspirin, Naproxen, and Diclofenac
by: Yousif Azeez, et al.
Published: (2025-04-01)

NEBIVOLOL SAFETY AS CARDIOSELECTIVE Β-BLOCKER IN COMPLEX THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE ACCOMPANIED BY CHRONIC OBSTRUCTIVE BRONCHITIS
by: Zh. G. Simonova, et al.
Published: (2003-10-01)

Quantitative determination of Nebivolol Hydrochloride and Rosuvastatin Calcium in laboratory prepared mixture by robust, high-performance liquid chromatographic method
by: Sandeep Bolla, et al.
Published: (2025-03-01)

The role of vasodilating β-blockers in patients with complicated hypertension: focus on nebivolol
by: T. D. Giles
Published: (2011-12-01)

CHRONIC HEART FAILURE OF ISCHEMIC GENESIS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: POSSIBILITIES OF COMBINATION THERAPY INCLUDING NEBIVOLOL
by: P. A. Fedotov, et al.
Published: (2014-07-01)

Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
by: A. G. Evdokimova, et al.
Published: (2005-04-01)

Nebivolol Exerts Hepatoprotective Activity During CLP-Induced Sepsis by Modulating Oxidative Stress, Liver Regeneration, and AKT/MAPK Pathways in Rats
by: Rahma Tharwat Sabra, et al.
Published: (2024-12-01)

Nebivolol, an FDA-Approved Drug, Has General Antibacterial and Antibiofilm Effects and Increases <i>Pseudomonas aeruginosa</i> Tolerance to Ciprofloxacin
by: Yael Schlichter Kadosh, et al.
Published: (2024-11-01)

The dynamics of 24-hour ambulatory blood pressure monitoring parameters, subclinical damage and endothelial function of vessels in patients with arterial hypertension and chronic obstructive pulmonary disease treated with S-amlodipine, Nebivolol and Enala
by: O. G. Ivanko, et al.
Published: (2017-02-01)

Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus
by: Yu. N. Belenkov, et al.
Published: (2011-02-01)

Development and Validation of a Rapid and Sensitive Ultrahigh-Performance Liquid Chromatography with Diode Array Detection Method for Quantification of Sertraline in Pharmaceutical Formulations
by: Tuğrul Çağrı Akman, et al.
Published: (2024-01-01)

COMPARE THE EFFECTIVENESS OF NEBIVOLOL AND SOTALOL IN PATIENTS WITH HYPERTENSIVE DISEASE AND VENTRICULAR ARRHYTHMIAS
by: I. Z. Shubitidze, et al.
Published: (2016-09-01)

Advanced eco-friendly spectrophotometric analysis for Nebivolol, Valsartan, and related impurity with comprehensive environmental impact assessment
by: Abdallah M. Hamdy, et al.
Published: (2025-05-01)

DFT analysis: correlation of epinephrine HOMO-LUMO, refractive index, optical electronegativity, and electrical conductivity with substituted halogens (F, Cl, Br)
by: Rebaz Obaid Kareem
Published: (2025-06-01)